Schlagwort: technology platforms
Part I: The Best Asset Doesn’t Have a Passport
For many years, Western biotech companies viewed China primarily as a manufacturing base and, increasingly, as an attractive commercial market. Today, that perspective is...
The Biotech IP Flip: Scaling Up Instead of Selling
Many European biotech companies still view the U.S. market primarily as a future exit channel. Yet it can be leveraged much earlier - not...

